Hyperpolarized Carbon-13 (13C) Pyruvate Imaging in Patients With Glioblastoma

Inclusion Criteria: * Cohort 1: Histologically proven newly diagnosed glioblastoma multiforme (GBM) who will undergo standard of treatment with radiation therapy (RT) and temozolomide (TMZ). * Cohort 2: Histologically proven recurrent suspected GBM who will receive surgical resection for the recurrence. * Cohort 3: Histologically proven recurrent suspected GBM who will undergo standard treatment for the recurrence. * Patients must be \>/= 18 years old and with a life expectancy \> 16 weeks. * Patients must have a Karnofsky performance status of ≥ 70. * Patients must have adequate renal function: creatinine \< 1.5 mg/dL before imaging. These tests must be performed within 60 days prior to Hyperpolarized Imaging scan. * Patients must not have any significant medical illnesses that in the investigator's opinion cannot be adequately controlled with appropriate therapy, would compromise the patient's ability to tolerate the imaging examination or any disease that will obscure toxicity or dangerously alter response to the imaging agent. * Patients must not have New York Heart Association (NYHA) Grade II or greater congestive heart failure * Patients must not have a history of myocardial infarction or unstable angina within 12 months prior to study enrollment. * This study was designed to include women and minorities, but was not designed to measure differences of intervention effects. Males and females will be recruited with no preference to gender. Minorities will actively be rec…